Jonathan Ejie | Personalized Medicine | Best Research Article Award

Posted on 04/07/202504/07/2025 by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Qun Tang | Drug Discovery and Development | Best Researcher Award

Posted on 02/07/202502/07/2025 by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer

Design and progress of drug-loading polymeric bead for tumor embolization

Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?

Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells

Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Posted on 02/07/202502/07/2025 by Top Pharmaceutical

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication Profile

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨‍⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration

Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC

Black Esophagus in Hyperosmolar Hyperglycemic Syndrome

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs

Solitary Cardiac Metastasis of Hepatocellular Carcinoma

Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome

Mario Romeo | Precision Medicine | Best Researcher Award

Posted on 02/07/202502/07/2025 by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis

Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review

Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?

Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications

Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?

Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?

FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis

Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report

Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Xinglong Zhong | Cardiovascular Pharmacology | Best Researcher Award

Posted on 02/07/202502/07/2025 by Top Pharmaceutical

Xinglong Zhong | Cardiovascular Pharmacology | Best Researcher Award

Prof. Xinglong Zhong, Department of Cardiology, The Fourth Affiliated Hospital of Guangxi Medical University/Liuzhou Workers’ Hospital, China

Prof. Xinglong Zhong is a dedicated cardiologist specializing in the diagnosis and treatment of cardiovascular diseases, with expertise in independent coronary angiography. 🏥 His clinical practice is complemented by a strong research background, focusing on vascular aging, myocardial fibrosis, and vascular calcification. 🔬 He has co-authored multiple peer-reviewed papers in prestigious SCI-indexed journals and has accumulated 244 citations with a top paper cited 127 times. 📊 His innovative work bridges interventional cardiology and molecular research, positioning him as a rising figure in cardiovascular science and precision medicine. 🌐❤️ His efforts continue to advance heart health through scientific discovery.

Publication Profile

Orcid

Education

Prof. Xinglong Zhong 🫀 is a skilled cardiologist specializing in the diagnosis and treatment of cardiovascular diseases, with particular expertise in independent coronary angiography. 🏥 His clinical proficiency is matched by a strong foundation in research, enabling him to bridge hands-on patient care with scientific innovation. 🔬 He has co-authored several peer-reviewed articles published in SCI-indexed journals, contributing valuable insights into vascular health and cardiology. 📚 His work exemplifies a harmonious integration of advanced interventional cardiology and active academic engagement, making him a vital contributor to both clinical excellence and medical research.

Professional Memberships

Prof. Xinglong Zhong 🩺 is currently not affiliated with any professional memberships or academic societies. While he does not hold formal memberships, his impactful research contributions and clinical expertise in cardiology speak volumes about his dedication to the field. 📚🧬 His work continues to gain recognition through high-quality publications and citation metrics, reflecting his independent commitment to advancing cardiovascular science. 🚀🔬 Despite the absence of organizational affiliations, Prof. Zhong remains a respected figure in both research and clinical communities, demonstrating that consistent innovation and scholarly excellence can shine through individual initiative and professional dedication.

Research Focus

Prof. Xinglong Zhong’s research focus lies in cardiovascular pathophysiology, with a special emphasis on vascular calcification, myocardial fibrosis, and molecular mechanisms of aging in chronic kidney disease. 🔍 His work explores the impact of gut-derived metabolites like trimethylamine-N-oxide (TMAO), inflammatory signaling pathways (NF-κB, NLRP3), and therapeutic agents such as puerarin and dihydromyricetin. 💊 He also investigates cutting-edge strategies like supramolecular hydrogels for cellular senescence and novel concepts like ion therapy in myocardial infarction. 🧪 His multidisciplinary approach bridges molecular cardiology and regenerative therapy, advancing precision treatment in heart and vascular diseases.

Publication Top Notes

Trimethylamine-N-oxide promotes vascular aging via inhibiting GATA4 degradation in chronic kidney disease rats

Enhanced fibrotic potential of COL1A1hiNR4A1low fibroblasts in ischemic heart revealed by transcriptional dynamics heterogeneity analysis at both bulk and single-cell levels

Lactobacillus rhamnosus GG aggravates vascular calcification in chronic kidney disease: A potential role for extracellular vesicles

Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling

Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-κB Signaling Pathway

Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals

β-Galactosidase instructed supramolecular hydrogelation for selective identification and removal of senescent cells

CDC42 promotes vascular calcification in chronic kidney disease

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Posted on 30/06/202530/06/2025 by Top Pharmaceutical

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Mr. Hiroyuki Minoura, Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Japan

Mr. Hiroyuki Minoura is a dedicated and accomplished researcher in computational biology and bioinformatics 🧬. With a solid academic foundation in science and technology 🎓, he has contributed to multiple research projects focused on systems pharmacology, precision medicine, and data-driven modeling 🧠. His work is widely cited in top scientific databases such as Scopus and Google Scholar 📊, and he has published in several high-impact journals 📝. Mr. Minoura is known for his interdisciplinary collaborations 🤝 and commitment to innovation in healthcare solutions. His research continues to bridge complex biological data and clinical applications for a better tomorrow.

Publication Profile

Google Scholar

Education

Mr. Hiroyuki Minoura 🎓 has built a strong academic and professional foundation rooted in research and innovation. With a solid educational background and years of experience in scientific study, he has contributed meaningfully to his field. His commitment to advancing knowledge is reflected in his work on cutting-edge research projects and industry collaborations. 🧪 Through consistent scholarly output and a keen focus on impactful solutions, Mr. Minoura has established himself as a promising leader in the research community. 🌍 His achievements not only demonstrate academic excellence but also highlight his potential to drive future advancements in science and technology.

Research and Innovations

Mr. Hiroyuki Minoura 🧠 has made remarkable strides in the realm of research and innovation. With a portfolio that includes numerous completed and ongoing research projects 🔬, he has consistently contributed to scientific progress. His publications in indexed journals 📚 and his registered patents 📄 reflect a commitment to cutting-edge discovery and practical application. Mr. Minoura’s impressive citation index 📈 underscores the influence of his work in the academic community. Additionally, his involvement in industry-sponsored projects 🤝 showcases the relevance and impact of his research beyond academia. His innovative contributions continue to shape advancements across multiple scientific disciplines.

Research Focus

Mr. Hiroyuki Minoura’s research focus lies at the nexus of surgical oncology and gastroenterology, concentrating on upper gastrointestinal malignancies—particularly gastric and esophagogastric junction cancers. 🏥🔬 He investigates appetite‑preserving gastrectomy, safe esophago‑jejunal reconstructions, and molecular crosstalk between cancer‑associated fibroblasts and the TGF‑β pathway, aiming to craft organ‑sparing, patient‑centred therapies. 🍽️🧬 His studies span bench to bedside: from laparoscopic innovations and “parachute” anastomosis techniques 🩺✂️ to translational biomarker discovery for precision medicine. 📊💉 Minoura also evaluates systemic regimens like mFOLFIRINOX for metastatic cases, bridging surgery with chemotherapy. 🚀 His holistic, innovation‑driven approach advances outcomes for complex digestive cancers worldwide patient survival.

Publication Top Notes

luis Guerra Sánchez | Drug Safety and Risk Management | Outstanding Contribution Award

Posted on 30/06/202530/06/2025 by Top Pharmaceutical

luis Guerra Sánchez | Drug Safety and Risk Management | Outstanding Contribution Award

Dr. luis Guerra Sánchez, HGU Gregorio Marañon, Spain

Dr. Luis Guerra Sánchez is an esteemed Spanish nurse and researcher with a Ph.D. in Nursing Care Research 🎓 from Universidad Complutense de Madrid. With degrees in Nursing (Graduate & Diploma) 🏥 and a Master’s in Nursing Research, his academic journey reflects excellence and dedication. He has completed over 40 advanced professional trainings 🧠, specializing in chronic care, diabetes, neonatal intensive care, statistics, leadership, and biomedical research 📊🧪. Dr. Sánchez is deeply committed to healthcare innovation, evidence-based practice, and continuous learning, making significant contributions to nursing education and clinical practice. A true advocate for patient-centered care and professional growth.

Publication Profile

Orcid

Education

Dr. Luis Guerra Sánchez holds a robust academic foundation in nursing, highlighted by a Ph.D. in Investigación en Cuidados de Enfermería 🎓 and a Master’s degree in Investigación en Cuidados from Universidad Complutense de Madrid 🏛️. His commitment to lifelong learning is evident in his completion of over 40 specialized training programs, covering diverse areas such as chronic patient care, diabetes management, neonatal intensive care, biomedical research, statistics, and healthcare leadership 📊🧪💉. With extensive experience in clinical and academic settings, Dr. Sánchez continues to contribute meaningfully to healthcare excellence and nursing advancement across Spain and beyond.

Awards

Dr. Luis Guerra Sánchez has pursued extensive professional development through a wide array of training programs and certifications 🎓. His credentials include courses in research methodology 🧪, statistical analysis 📊, and healthcare management 🏥. He holds specialized certifications in critical care 🚑, cardiology ❤️, and neonatology 👶, reflecting his deep commitment to high-level clinical expertise. With over four decades of continuous learning, his qualifications span from advanced clinical practices to leadership and teaching in healthcare. These achievements underline his dedication to excellence and innovation in patient care, nursing education, and evidence-based medical practice.

Experience

Dr. Luis Guerra Sánchez brings a wealth of experience in both clinical practice and scientific research 🏥📚. His professional journey spans diverse healthcare settings, where he has contributed significantly through patient care, management, and academic mentoring 👨‍⚕️👨‍🏫. With numerous certifications and continuous training in specialized areas such as cardiology, neonatology, and chronic disease management ❤️👶, he exemplifies lifelong learning. His involvement in research projects and data-driven healthcare innovations reflects a strong dedication to evidence-based practice and improving patient outcomes 🔎📈. Dr. Sánchez’s impact extends across clinical, educational, and investigative domains, making him a leader in modern nursing.

Research Focus

Dr. Luis Guerra Sánchez’s scholarship sits at the crossroads of clinical nutrition, cardiovascular nursing, and patient‑safety science. His randomized trials explore how tailored dietary strategies can reverse malnutrition, boost functional capacity, and elevate quality of life in chronic heart‑failure patients 🫀📈. Parallel work standardises intravenous therapies and analgesia–sedation practices in ICUs, tightening medication‑safety protocols 💉🔒. Through multicentre audits, he spotlights delirium, restraint use, and nutritional risk—generating evidence for nurse‑led interventions that cut complications and hospital days 🏥⏱️. Overall, Luis champions evidence‑based, nurse‑driven care models that fuse nutrition science with cardiology and critical‑care best practices, improving outcomes across vulnerable populations .

Publication Top Notes

Effect of a double nutritional intervention on the nutritional status, functional capacity, and quality of life of patients with chronic heart failure: 12-month results from a randomized clinical trial

Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety.

Assessment of analgesia, sedation, physical restraint and delirium in patients admitted to Spanish intensive care units. Proyecto ASCyD

Nutritional intervention in patients with heart failure. 3 month results of a clinical trial

[Prevalence of undernutrition in hospital patients with unbalanced heart failure; subjective global assessment like prognosis sign].

[Nutritional screening in heart failure patients: 5 methods review].

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Posted on 24/06/202524/06/2025 by Top Pharmaceutical

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Dr. José Leite, Universidade de Brasília – UnB, Brazil

Dr. José Roberto Leite is a Brazilian biochemist and molecular biologist with a PhD from the University of Brasília 🇧🇷 and postdoctoral training at EMBRAPA and the University of Porto 🇵🇹. He is an Associate Professor at UnB’s Faculty of Medicine and Visiting Researcher at i3S. 🧪 As co-founder of People&Science, he works on biotechnology, nanobiotech, and bioactive peptides for health and environment 🌿. With 200+ international publications 📚, patents under development 💡, and global collaborations 🌍, he bridges biodiversity and innovation. Dr. Leite also serves as Associate Editor of the Journal of Global Innovation.

Publication Profile

Google Scholar

Education

Dr. José Roberto Leite earned his PhD in Biological Sciences (Biochemistry/Molecular Biology) from the University of Brasília 🇧🇷 and completed postdoctoral training at EMBRAPA and the University of Porto (REQUIMTE) 🇵🇹. He serves as an Associate Professor at UnB’s Faculty of Medicine and is a Visiting Researcher at i3S 🧬. He coordinated graduate programs at UFPI and UnB and founded the Biotec/UFPI research group 🧑‍🔬. As co-founder of People&Science, he leads cutting-edge work in biotechnology, nanobiotechnology, and bioprospecting for health and the environment 🌱. He is also Associate Editor of the Journal of Global Innovation 📘 and promotes international collaboration.

Professional Memberships

Dr. José Roberto Leite is actively engaged in Brazil’s leading scientific communities and holds esteemed memberships in the Brazilian Society for Biochemistry and Molecular Biology 🧪 and the Brazilian Society of Biotechnology 🧬, reflecting his deep commitment to advancing life sciences and innovation. In addition, he plays a key editorial role 📖 in the Journal of Global Innovation (JGI), contributing to the dissemination of cutting-edge research and fostering interdisciplinary collaboration 🌐. His involvement in these professional circles underscores his dedication to scientific excellence, knowledge sharing, and the promotion of impactful biotechnology and molecular biology initiatives across Brazil and beyond.

Research Focus

Dr. José Roberto Leite focuses on cutting-edge research in biotechnology, nanobiotechnology, and natural product-based drug discovery 🌱. His work spans the development of bioactive peptides 🧬, antimicrobial and anticancer compounds 💊, and innovative drug delivery systems 🚀. He explores biodiversity to identify novel molecules from amphibians 🐸, plants 🌿, and marine life 🌊 for therapeutic and diagnostic applications. Dr. Leite also contributes to the advancement of biosensors, nutraceuticals, and functional biomaterials. His interdisciplinary research bridges biochemistry, molecular biology, and pharmacology, driving translational science for global health and environmental impact.

Publication Top Notes

Dermaseptins from Phyllomedusa oreades andPhyllomedusa distincta: ANTI-TRYPANOSOMA CRUZI ACTIVITY WITHOUT CYTOTOXICITY TO MAMMALIAN CELLS

Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the Phyllomedusa genus

Transtornos de ansiedade e exercício físico

Identification of a cowpea γ‐thionin with bactericidal activity

Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens

Medical students, spirituality and religiosity-results from the multicenter study SBRAME

Anti-inflammatory and Antinociceptive Activity of Epiisopiloturine, an Imidazole Alkaloid Isolated from Pilocarpus microphyllus

Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia)

Development and antibacterial activity of cashew gum-based silver nanoparticles

Antinociceptive activity of the monoterpene α-phellandrene in rodents: possible mechanisms of action

The NMR-derived solution structure of a new cationic antimicrobial peptide from the skin secretion of the anuran Hyla punctata

Antidiarrheal activity of cashew GUM, a complex heteropolysaccharide extracted from exudate of Anacardium occidentale L. in rodents

Vibeke Strand | Clinical Trials | Best Researcher Award

Posted on 24/06/202524/06/2025 by Top Pharmaceutical

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Hoda Salem | Clinical Trials | Best Researcher Award

Posted on 24/06/202524/06/2025 by Top Pharmaceutical

Hoda Salem | Clinical Trials | Best Researcher Award

Prof. Dr. Hoda Salem, University of Tabuk, Saudi Arabia

Prof. Dr. Hoda Salem 🎓 is a distinguished clinical pharmacy expert with a Ph.D. in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. With over two decades of academic and clinical experience, she currently serves as Professor at Tabuk University, Saudi Arabia 🇸🇦. She has led numerous funded research projects, particularly in neuropharmacology and pharmacogenetics 🧬🧠. A prolific scholar, Dr. Salem has published in Q1 journals 📚 and actively mentors Ph.D. and MSc students. Her contributions extend to curriculum development, hospital training, and quality assurance in education 🌍. She’s a driving force in pharmacy education and clinical research excellence.

Publication Profile

Google Scholar

Education

Prof. Dr. Hoda Salem 🎓 earned her Bachelor’s degree in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. She continued her academic journey with a Master’s degree (M.Sc.) in Clinical Pharmacy from the same university, demonstrating early on her commitment to specialized healthcare and pharmaceutical practice 💊. Her pursuit of excellence culminated in a Ph.D. in Clinical Pharmacy in 2008 🧪, also from Tanta University. This strong academic foundation laid the groundwork for her impactful career in clinical pharmacy, education, and research, making her a respected figure in both Egyptian and international pharmaceutical education and clinical advancement.

Experience

Prof. Dr. Hoda Salem ⚕️ has made significant contributions to both scientific and clinical work in pharmacy education and healthcare. She played a pivotal role in quality assurance and accreditation by leading the self-study efforts and contributing to strategic planning at Tabuk and Al-Azhar Universities 📊📚. As a committee member, she helped supervise undergraduate examinations and mentored numerous Ph.D. and M.Sc. research projects 🎓🧬. Her clinical work includes patient counseling, drug dispensing, and providing accurate drug information to healthcare professionals at Tanta University Hospitals 💊🏥, reinforcing her commitment to enhancing both education and patient care.

Research Focus

Prof. Dr. Hoda Salem’s 🧪 research focus lies in clinical pharmacy, pharmaceutics, and neuropharmacology with a multidisciplinary approach integrating nanotechnology, drug delivery systems, and natural compounds. Her publications explore the treatment of diseases such as Alzheimer’s 🧠, Parkinson’s, ADHD, and fungal infections, along with oncology 🧬 and pharmacogenetics in breast cancer therapy. She has also worked on innovative therapies like solid lipid nanoparticles, niosomal gels, and bone marrow stem cell applications. Her clinical trials and lab studies reflect a deep commitment to therapeutic innovation, patient care, and translational research 💊🔬, bridging pharmaceutical science and clinical outcomes for better healthcare.